The legal complaint contends that Fractyl Health executives issued materially false statements concerning the company’s core operations. Central to the allegations is the claim that the Revita procedure performed below expectations, while clinical site issues within the REMAIN-1 Midpoint Cohort undermined the validity of reported efficacy data. Plaintiffs argue these omissions led to an inflated assessment of the firm’s commercial and regulatory prospects.

Shareholders who purchased GUTS stock during the specified window are encouraged to review their legal options. While those who held shares during this period are automatically considered class members, individuals seeking a more active role in the litigation must file for lead plaintiff status before the mid-October deadline. Interested parties can reach the Law Offices of Howard G. Smith at 215-638-4847 or via their website to discuss the requirements for participation.